

GMO INTERNATIONAL DEVELOPED EQUITY ALLOCATION SERIES FUND R6

OVERVIEW

The GMO International Developed Equity Allocation Series Fund (the "Fund") seeks total return greater than that of the MSCI EAFE Index. The Fund uses multi-year forecasts of returns among asset classes to build a portfolio that typically provides exposure to non-U.S. equity markets.

PORTFOLIO MANAGEMENT



Ben Inker, CFA

- Joined GMO in 1992
- 28 yrs industry experience
- B.A. from Yale University



John Thorndike

- Joined GMO in 2015
- 16 yrs industry experience
- A.B. from Bowdoin College

Performance Net of Fees (USD) - Share Class R6

TOTAL RETURN (%)

	<i>Portfolio</i>	<i>MSCI EAFE</i>
MTD	12.39	15.50
QTD	8.24	10.89
YTD	0.88	3.03

ANNUAL TOTAL RETURN (%)

2019	24.08	22.01
2018	-19.50	-13.79
2017	26.00	25.03
2016	3.17	1.00
2015	-6.70	-0.81
2014	-5.88	-4.90
2013	24.17	22.78
2012	17.06	17.32
2011	-9.49	-12.14
2010	10.79	7.75

Returns shown for periods greater than one year are on an annualized basis.

If certain expenses were not reimbursed, performance would be lower. Transaction costs, if any, are paid to the fund to offset the cost of portfolio transactions to invest or raise cash.

GMO International Developed Equity Allocation Series Fund is a feeder fund investing substantially all of its assets in shares of a corresponding GMO Trust master fund. The GMO International Developed Equity Allocation Series Fund inceptioned on January 12, 2015. Returns prior to that inception date are shown back to the GMO Trust master fund's inception date and reflect the performance data of the corresponding GMO Trust master fund re-stated to reflect the fees and expenses associated with GMO International Developed Equity Allocation Series Fund. The effect of purchase premiums and redemption fees paid by the Series Fund to the GMO Trust master fund are not reflected for periods prior to the date on which the Series Fund commenced operations. If the effect of these payments were reflected, returns for periods prior to the date on which the Series Fund commenced operations would be less than those shown.

Performance data quoted represents past performance and is not indicative of future results. The investment return and principal value of an investment will fluctuate so that an investor's shares, when redeemed, may be worth more or less than their original cost. Current performance data may be lower or higher than the performance data provided herein. To obtain performance information to the most recent month-end, visit www.gmo.com.

An investor should consider the fund's investment objectives, risks, charges and expenses before investing. This and other important information can be found in the funds prospectus. To obtain a prospectus please visit www.gmo.com. Read the prospectus carefully before investing.

Each GMO Series Trust Fund is a feeder fund investing substantially all of its assets in shares of a corresponding GMO Trust Fund (i.e., a master fund). Under the master-feeder structure, each GMO Series Trust Fund's sole portfolio holding, other than cash, is shares of the corresponding GMO Trust Fund. The GMO Trust funds are distributed in the United States by Funds Distributor LLC. GMO and Funds Distributor LLC are not affiliated.


Risks associated with investing in the Fund may include those as follows. (1) Market Risk - Equities: The market price of an equity may decline due to factors affecting the issuer or its industry or the economy and equity markets generally. Declines in stock market prices generally are likely to reduce the net asset value of the Fund's shares. (2) Non-U.S. Investment Risk: The market prices of many non-U.S. securities (particularly of companies tied economically to emerging countries) fluctuate more than those of U.S. securities. Many non-U.S. markets (particularly emerging markets), are less stable, smaller, less liquid, and less regulated than U.S. markets, and the cost of trading in those markets often is higher than it is in U.S. markets. (3) Management and Operational Risk: The risk that GMO's investment techniques will fail to produce desired results. For a more complete discussion of these risks and others, please consult the Fund's prospectus.

FACTS: Share Class R6

Fund Inception Date	January 12, 2015
Benchmark	MSCI EAFE
Total Assets as of 11/30/20	\$11mm USD
Ticker Symbol	GIDRX
CUSIP	380131359
Net Expense Ratio	0.68
Gross Expense Ratio	0.68

Net Expense Ratio reflects the reduction of expenses from fee reimbursements. The fee reimbursements will continue until at least June 30, 2021. Elimination of this reimbursement will result in higher fees and lower performance. Gross Expense Ratio is equal to the Funds Total Annual Operating Expenses set forth in the Funds most recent prospectus dated June 30, 2020.

ANNUALIZED RETURNS (%) AS OF 09/30/2020



Master Fund Inception Date: June 5, 2006


GMO INTERNATIONAL DEVELOPED EQUITY ALLOCATION SERIES FUND R6

CHARACTERISTICS

	<i>Portfolio</i>	<i>MSCI EAFE</i>
Price/Earnings - Hist 1 Yr Wtd Mdn	18.8x	29.9x
Price/Book - Hist 1 Yr Wtd Avg	1.6x	1.7x
Price/Cash Flow - Hist 1 Yr Wtd Mdn	10.0x	15.7x
Return on Equity - Hist 1 Yr Mdn	12.8%	9.9%
Market Cap - Wtd Mdn Bil	20.1 USD	33.8 USD
Number of Equity Holdings	684	896


The above information is based on the corresponding GMO Trust master fund.

PORTFOLIO ALLOCATIONS (%)



Weightings are as of the date indicated and are subject to change. The groups indicated above represent exposures determined pursuant to proprietary methodologies and are subject to change over time. Totals may vary due to rounding. The above information is based on the corresponding GMO Trust master fund. Group weights under 1% are not reflected.

TOP COUNTRIES (%)



The above information is based on the corresponding GMO Trust master fund.

The Fund invests substantially all of its assets in GMO International Developed Equity Allocation Fund ("IDEAF"), which invests primarily in shares of other funds managed by GMO. The Fund's investment objective and principal investment strategies, therefore, are substantially similar to those of IDEAF. References to the Fund may refer to actions undertaken by the Fund or IDEAF.

The MSCI EAFE (Europe, Australasia, and Far East) Index (MSCI Standard Index Series, net of withholding tax) is an independently maintained and widely published index comprised of international large and mid capitalization stocks. MSCI data may not be reproduced or used for any other purpose. MSCI provides no warranties, has not prepared or approved this report, and has no liability hereunder.

RISK PROFILE - 5-YEAR TRAILING

	<i>Portfolio</i>	<i>MSCI EAFE</i>
Alpha (Jensen's)	-1.19	N/A
Beta	1.00	N/A
R Squared	0.93	N/A
Sharpe Ratio	0.24	0.33
Standard Deviation	15.84	15.18

Alpha is a measure of risk-adjusted return. Beta is a measure of a portfolio's sensitivity to the market. R-Squared is a measure of how well a portfolio tracks the market. Sharpe Ratio is the return over the risk free rate per unit of risk. Std Deviation is a measure of the volatility of a portfolio. Risk profile data is net. The above information is based on the corresponding GMO Trust master fund.

TOP HOLDINGS

<i>Company</i>	<i>Country</i>	<i>Sector</i>	<i>%</i>
Roche Holding AG	Switzerland	Health Care	3.0
KDDI Corp	Japan	Communication Services	2.2
British American Tobacco PLC	United Kingdom	Consumer Staples	2.2
Fortescue Metals Group Ltd	Australia	Materials	2.1
DBS Group Holdings Ltd	Singapore	Financials	2.1
Sanofi	France	Health Care	2.0
Nippon Telegraph & Telephone Corp	Japan	Communication Services	2.0
Rio Tinto Ltd	Australia	Materials	1.9
Enel SpA	Italy	Utilities	1.7
Astellas Pharma Inc	Japan	Health Care	1.7
Total			20.9

GICS Sector. The above information is based on the corresponding GMO Trust master fund. Portfolio holdings are percent of equity. Where applicable, the top holdings are derived by looking through to the underlying funds in which the asset allocation funds invest and, where appropriate, individual security positions are aggregated. They are subject to change and should not be considered a recommendation to buy individual securities.



About GMO: Founded in 1977, GMO is a private partnership whose sole business is investment management. The firm manages global portfolios with offices and clients around the world. Investment offerings include equity, fixed income, multi-asset class, and alternative strategies. GMO is known for blended fundamental and quantitative investment research expertise and a long-term orientation toward value opportunities.